Macrophage depletion is a powerful research method for comprehensively understanding macrophage function under pathological conditions. Clodronate Liposomes are currently the most mature, convenient, and cost-effective tool for macrophage depletion, effectively eliminating macrophages in various tissues and the bloodstream in animal models.
Composition and Mechanism of Clodronate Liposomes
Disodium Clodronate is a bisphosphonate drug primarily used clinically for osteolytic bone metastases caused by cancer, osteoporosis, and hypercalcemia. Its mechanism of action involves intracellular metabolism into non-hydrolyzable ATP analogs, which inhibit the ADP/ATP translocase in mitochondria, thereby blocking the mitochondrial respiratory chain and inducing apoptosis. However, due to its low lipophilicity, free clodronate cannot cross cell membranes. After oral or intravenous administration, the free drug reaches its half-life within 2 hours, and 80% is excreted in urine within 48 hours.
Liposomes are spherical vesicles composed of single or multiple lipid bilayers, primarily made of phospholipids and cholesterol. As non-toxic carriers, they transport molecular substances into cells by fusing with the cell membrane.
When clodronate is encapsulated in the aqueous phase of liposomes, it cannot freely cross the phospholipid bilayer. After injection into a biological system, clodronate liposomes are phagocytized by macrophages. Inside the macrophages, lysosomal phospholipases gradually dissolve the liposomes, releasing and accumulating clodronate within the cell. Once a certain concentration is reached, the macrophages suffer irreversible damage and undergo apoptosis. The clodronate from dead cells is then released extracellularly and excreted via urine.
Product Specifications
Clodronate Content: ~5 mg per 1 mL of liposome suspension.
Liposome Diameter: 1.5–2 μm.
Buffer: Phosphate-buffered saline (PBS) containing 10 mM Na₂HPO₄, 10 mM NaH₂PO₄, and 140 mM NaCl.
Key Usage Guidelines
Aseptic Technique: Always use sterile techniques when extracting the product from the vial. Do not use if sterility is compromised.
Resuspension: Liposomes may settle after standing for several hours. Before use, gently invert the vial several times to ensure a uniform suspension. Do not shake or vortex vigorously.
Animal Health: Animal immunity begins to decline within hours after injection. Monitor animal health closely to prevent unrelated infections.
Immunodeficient Mice: High mortality is expected if used in immunodeficient mice.
Intravenous (IV) Injection: Warm the reagent to room temperature (18 °C) and remove air bubbles from the syringe. Inject slowly. If the animal shows any abnormal reactions, reduce the injection speed.
Storage: Store at 4 °C. DO NOT FREEZE.
In Vivo Injection Protocol (For Reference Only)
Tail Vein Injection Method:
Restraint: Secure the mouse and extend the tail. The mouse tail has 2 arteries (dorsal and ventral) and 3 veins arranged in an inverted triangle. The lateral veins are typically used for injection.
Vein Dilation: Wrap the tail in gauze soaked in warm water (~70 °C) to dilate the blood vessels and soften the epidermis.
Injection: Pinch the tail with your left thumb and index finger to leave a ~2 cm section, making the skin taut and the vein engorged. Hold a 1 mL syringe in your right hand, align the needle parallel to the vein (at an angle of <30°), and insert it into the lower 1/4 of the tail. Inject slowly. If there is no resistance and no white bleb forms, the needle is in the vein, and injection can proceed.
Sequential Injections: For continuous IV injections, start from the distal end of the tail and move proximally, alternating injection sites. After withdrawing the needle, apply gentle pressure with a cotton ball for 1–2 minutes to achieve hemostasis.
[Note]: The above methods and dosages are for reference only. Please design your own experimental protocols or refer to relevant literature for specific studies.
Efficacy Demonstration
Reference Case 1
Figure 3. Flow cytometric analysis of Kupffer cell depletion in murine liver.
The left panel shows the proportion of Kupffer cells among normal hepatic immune cells in mice. The right panel shows the proportion of Kupffer cells 48 hours post-injection of Clodronate Liposomes, demonstrating that Kupffer cells are essentially depleted [1].
Reference Case 2
Figure 4. Immunofluorescence imaging of macrophage infiltration in murine LLC lung cancer tissues.
The images compare macrophage distribution (indicated by red fluorescence) in normal tumor tissues against tissues following intratracheal instillation of Clodronate Liposomes. The results indicate that macrophages within the tumor microenvironment are essentially depleted after liposome administration [2]
Experimental Methods for Macrophage Depletion in Different Tissues
|
Target Organ/ Cell Type |
Experimental Protocol |
|
Spleen/ Red Pulp Macrophages |
Single Dose: 200 μL/mouse (intravenous [IV] or intraperitoneal [IP] injection). |
|
Liver/ Kupffer Cells |
Single Dose: 200 μL/mouse (IV or IP injection). |
|
Lung/ Alveolar Macrophages |
Optimal depletion is achieved by combining IV injection (150–200 μL) with intratracheal or intranasal administration (50 μL). |
|
Lymph Nodes |
100–200 μL/mouse via injection. Please refer to relevant literature for specific administration routes. |
|
Brain/ Microglia |
Intracerebroventricular (ICV) injection: 10 μL/mouse or 50 μL/rat. |
Frequently Asked Questions (FAQ)
Q1: How should I handle Clodronate Liposomes upon receipt?
A: Store at 4 °C if not using immediately. DO NOT FREEZE. Use as a stock solution; do not dilute. Liposomes settle easily, so gently mix before use. If stored at 4 °C, warm to room temperature before injection.
Q2: How do I transfer liposomes from the vial?
A: The best method is using a sterile needle and syringe to maintain a sealed and clean environment. Alternatively, use a sterile pipette tip in a clean environment, such as a Biosafety Cabinet (BSC).
Q3: Can Clodronate Liposomes be used for in vitro macrophage depletion?
A: Yes, but they are primarily designed for in vivo use. In vitro, clodronate released from dead cells or leaked from liposomes accumulates in the culture medium. Over time, this free clodronate can enter cells and cause toxicity. In vivo, free clodronate has a short half-life and is rapidly cleared by the kidneys.
Q4: Why did the animal die shortly after IV injection of Clodronate Liposomes?
A: This is often due to injecting an uneven suspension. Gently mix before use. If injecting multiple animals over a long period, liposomes may settle in the syringe, causing the first animal to receive a lower dose and the last animal a much higher dose. Another common cause is injecting the liposomes directly from 4 °C without warming to room temperature.
Q5: Why did the animal die a few days after injection?
A: This is likely due to bacterial contamination. Macrophage depletion increases susceptibility to infections by viruses, bacteria, or yeast. Ensure strict aseptic technique.
Q6: Why didn't all ED1+ cells disappear in the rat spleen/liver after IV injection?
A: In rats, mature macrophages are ED1+/ED2+. However, some precursor cells with low or no phagocytic activity are ED1+/ED2-. While all ED2+ cells are completely depleted, only a portion of ED1+ cells are cleared, depending on the ratio of precursor to mature macrophages.
Q7: Clodronate Liposomes did not achieve the expected depletion effect. Why?
A: Every batch is rigorously tested for clodronate concentration and contaminants before release. Liposomes are sensitive to extreme temperatures. Ensure proper transport and storage at 4–8 °C. Do not freeze or heat above 30 °C. Use within 3 months of receipt to ensure optimal efficacy.
Q8: Can I increase the injection volume for IV administration?
A: For IV injection, do not exceed 0.1 mL per 10 g of body weight. Intraperitoneal (IP) injection allows for larger volumes. Subcutaneous (SC) injection volume depends on the capacity of the injection site.
Q9: What precautions should I take when handling liposomes?
A: Although liposomes made with saturated hydrocarbon chains are highly stable, please observe the following:
Do not mix with organic solvents (e.g., chloroform, methanol, ethanol, DMSO, ether).
Do not add surfactants unless you intentionally want to lyse the liposomes.
Do not heat to or above the lipid main phase transition temperature, unless performing drug loading (which requires incubation above the transition temperature).
References
[1]. Guan Z, Ding Y, Liu Y, Zhang Y, Zhao J, Li C, Li Z, Meng S. Extracellular gp96 is a crucial mediator for driving immune hyperactivation and liver damage. Sci Rep. 2020 Jul 28;10(1):12596. doi: 10.1038/s41598-020-69517-7. PMID: 32724151; PMCID: PMC7387550.1
[2]. Li R, Yang L, Jiang N, Wang F, Zhang P, Zhou R, Zhang J. Activated macrophages are crucial during acute PM2.5 exposure-induced angiogenesis in lung cancer. Oncol Lett. 2020 Jan;19(1):725-734. doi: 10.3892/ol.2019.11133. Epub 2019 Nov 21. PMID: 31897188; PMCID: PMC6924157.2